ODI Pharma AB (publ) reported earnings results for the fourth quarter and full year ended June 30, 2023. For the fourth quarter, the company reported sales was SEK 0.038418 million compared to SEK 0.014233 million a year ago. Revenue was SEK 0.038446 million compared to SEK 0.050125 million a year ago. Net loss was SEK 1.9 million compared to SEK 2.38 million a year ago. Basic loss per share from continuing operations was SEK 0.12 compared to SEK 0.16 a year ago.
For the full year, sales was SEK 0.139457 million compared to SEK 0.544151 million a year ago. Revenue was SEK 0.178323 million compared to SEK 0.632022 million a year ago. Net loss was SEK 6.16 million compared to SEK 7.3 million a year ago. Basic loss per share from continuing operations was SEK 0.4 compared to SEK 0.48 a year ago.